Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| oligodendrocyte | 17 studies | 53% ± 17% | |
| transit amplifying cell | 3 studies | 38% ± 28% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 6 studies | 33% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 98% | 6564.97 | 2593 / 2642 | 92% | 46.09 | 647 / 705 |
| skin | 92% | 4308.48 | 1665 / 1809 | 90% | 37.01 | 427 / 472 |
| esophagus | 65% | 888.11 | 943 / 1445 | 99% | 70.06 | 181 / 183 |
| intestine | 37% | 262.27 | 360 / 966 | 95% | 33.89 | 502 / 527 |
| stomach | 28% | 257.65 | 100 / 359 | 95% | 34.42 | 272 / 286 |
| lung | 22% | 185.03 | 126 / 578 | 90% | 35.63 | 1034 / 1155 |
| uterus | 4% | 30.45 | 6 / 170 | 97% | 51.91 | 444 / 459 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 51.25 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 7.14 | 1 / 1 |
| ovary | 10% | 79.36 | 18 / 180 | 88% | 17.49 | 379 / 430 |
| bladder | 5% | 23.19 | 1 / 21 | 91% | 35.13 | 458 / 504 |
| breast | 6% | 34.99 | 28 / 459 | 86% | 28.21 | 958 / 1118 |
| pancreas | 1% | 6.82 | 3 / 328 | 77% | 16.64 | 137 / 178 |
| lymph node | 0% | 0 | 0 / 0 | 55% | 8.62 | 16 / 29 |
| liver | 5% | 45.47 | 12 / 226 | 33% | 5.57 | 132 / 406 |
| adrenal gland | 12% | 73.54 | 32 / 258 | 22% | 5.02 | 50 / 230 |
| spleen | 27% | 168.49 | 66 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 27% | 620.57 | 248 / 929 | 0% | 0 | 0 / 0 |
| kidney | 3% | 49.03 | 3 / 89 | 21% | 3.59 | 190 / 901 |
| blood vessel | 14% | 80.23 | 187 / 1335 | 0% | 0 | 0 / 0 |
| thymus | 2% | 9.28 | 14 / 653 | 11% | 1.81 | 69 / 605 |
| prostate | 3% | 43.78 | 8 / 245 | 8% | 1.12 | 41 / 502 |
| adipose | 11% | 75.89 | 136 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 5% | 0.40 | 4 / 80 |
| heart | 5% | 32.31 | 39 / 861 | 0% | 0 | 0 / 0 |
| muscle | 0% | 6.91 | 3 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0002244 | Biological process | hematopoietic progenitor cell differentiation |
| GO_0000921 | Biological process | septin ring assembly |
| GO_0031106 | Biological process | septin ring organization |
| GO_0007096 | Biological process | regulation of exit from mitosis |
| GO_0000915 | Biological process | actomyosin contractile ring assembly |
| GO_0000281 | Biological process | mitotic cytokinesis |
| GO_1904172 | Biological process | positive regulation of bleb assembly |
| GO_0090521 | Biological process | podocyte cell migration |
| GO_0032059 | Cellular component | bleb |
| GO_0015629 | Cellular component | actin cytoskeleton |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0030496 | Cellular component | midbody |
| GO_0005938 | Cellular component | cell cortex |
| GO_0005826 | Cellular component | actomyosin contractile ring |
| GO_0045296 | Molecular function | cadherin binding |
| GO_0003779 | Molecular function | actin binding |
| Gene name | ANLN |
| Protein name | Anillin, actin binding protein Anillin |
| Synonyms | |
| Description | FUNCTION: Required for cytokinesis . Essential for the structural integrity of the cleavage furrow and for completion of cleavage furrow ingression. Plays a role in bleb assembly during metaphase and anaphase of mitosis . May play a significant role in podocyte cell migration . . |
| Accessions | H7C3S1 ENST00000457743.1 ENST00000428612.5 H7C1K5 ENST00000418118.1 H7C1C2 H7C0Y6 C9JJT6 ENST00000441696.5 H7C167 ENST00000396068.6 [Q9NQW6-2] ENST00000265748.7 [Q9NQW6-1] ENST00000446635.5 Q9NQW6 ENST00000452877.5 H7C3R2 ENST00000424865.1 C9J0G4 ENST00000429082.1 |